NEUROENDOCRINE TUMOR G2
Clinical trials for NEUROENDOCRINE TUMOR G2 explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE TUMOR G2 trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE TUMOR G2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for slowing advanced neuroendocrine tumors in major trial
Disease control OngoingThis study is testing if a drug called cabozantinib can slow the growth of advanced neuroendocrine tumors better than a placebo (inactive pill). It is for about 298 patients whose cancer has continued to grow despite receiving at least one prior standard treatment. The main goal …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Major cancer trial tests new drug duos for rare, aggressive tumors
Disease control OngoingThis large Phase 3 trial aims to find the better treatment combination for patients with advanced, high-risk neuroendocrine tumors (like carcinoid tumors) that have spread. Researchers are comparing a standard drug (octreotide) paired with either interferon or bevacizumab to see …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial aims to halt rare Cancer's spread
Disease control OngoingThis study is testing whether a drug called pazopanib can slow or stop the growth of carcinoid tumors that are getting worse. It compares pazopanib against a placebo (inactive pill) in 171 patients whose tumors have progressed. The main goal is to see if the drug helps patients l…
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC